Invion Stock

Invion Interest Expense

The Interest Expense of Invion (IVX.AX) as of Sep 3, 2026 is -694,800.00 AUD. In the previous year, Interest Expense was -240,000.00 AUD — a change of 189.50% (lower).

Interest Expense

-694,800.00AUD

YoY

189.50%

Last updated:

Interest Expense of Invion is 2026 -694,800.00 AUD. Interest Expense of Invion was 2025 -240,000.00 AUD. It decreases by 189.50% lower compared to the previous year.

The Invion Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2016
-199,600.00 AUD
Jan 1, 2017
-144,400.00 AUD
Jan 1, 2018
-117,900.00 AUD
Jan 1, 2019
-34,500.00 AUD
Jan 1, 2020
4,600.00 AUD
Jan 1, 2022
100.00 AUD
Jan 1, 2024
-240,000.00 AUD
Jan 1, 2025
-694,800.00 AUD
The Invion Interest Expense history
YEARInterest ExpenseYoY
-694,800.00AUD+189.50%
-240,000.00AUD-240,100.00%
100.00AUD-97.83%
4,600.00AUD-113.33%
-34,500.00AUD-70.74%
-117,900.00AUD-18.35%
-144,400.00AUD-27.66%
-199,600.00AUD-82.70%
-1.15 MAUD+1,053.60%
-100,000.00AUD—
Access this data via the Eulerpool API
Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Interest Expense of Invion is -694,800.00 AUD in 2026.

Interest Expense of Invion changed from -240,000.00 AUD to -694,800.00 AUD, representing a 189.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Invion since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Invion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Invion

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Invion